Strategic cooperation

SpeeDx and Cepheid announce partnership on European distribution

SpeeDx Pty, Ltd. announced an agreement with Cepheid for distribution of its PlexPCRTM and ResistancePlusTM molecular diagnostic products in key markets throughout Europe. The agreement, covering Germany, France, Italy, and the UK, will increase coverage for the market-leading ResistancePlus MG test, the first CE-IVD test for Mycoplasma genitalium to combine detection with testing for azithromycin resistance.

ResistancePlusTM MG assay.
ResistancePlusTM MG assay.
Source: SpeeDx

The timing of the agreement coincides with recent guideline changes across Europe recommending M. genitalium resistance screening in the management of non-gonococcal urethritis. The inclusion of a macrolide resistance test when detecting M. genitalium provides clinicians with much needed information to guide antibiotic treatment. Resistance to frontline antibiotic treatment is increasing and has been observed in up to 50 % of M. genitalium positive patients in recent studies. “This partnership is a true win-win,” said Colin Denver, CEO of SpeeDx. “We gain better access to these important European markets and Cepheid can bring its customers a comprehensive test for M. genitalium and azithromycin resistance.”

“SpeeDx offers a unique approach to simultaneous detection of pathogens and drug resistance directly from clinical specimens, consistent with Cepheid's approach to detecting tuberculosis,” said David H. Persing, MD, Ph.D., Cepheid’s Chief Medical and Technology Officer. "This technology could potentially be applied in multiple settings in which actionable treatment information is needed quickly."

 

Source: SpeeDx

09.06.2017

Read all latest stories

Related articles

Research

Genetic alterations

This article discusses examples of applications of genetic analyses in coagulation disorders and haematological and oncological diseases. Professor Christine Mannhalter highlights the impact changes…

Politics I

Austria’s notable national action plan

Surveillance, hygiene and infection prevention, antimicrobial stewardship, diagnosis of infectious diseases, use of antimicrobial medicines as well as reporting and information.

A chip placed under the skin for more precise medicine

Several EPFL laboratories are working on devices allowing constant analysis over as long a period as possible. The latest development is the biosensor chip, created by researchers in the Integrated…

Related products

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd

LIS, Middleware, POCT

Beckman Coulter - REMISOL Advance

Beckman Coulter, Inc.

Clinical chemistry

DiaSys Diagnostic Systems - InnovaStar

DiaSys Diagnostic Systems GmbH

PET-CT

GE Healthcare - Discovery IQ

GE Healthcare